Search

Coloplast A-S (Class B)

Gesloten

569.8 -0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

564.4

Max

579.4

Belangrijke statistieken

By Trading Economics

Inkomsten

70M

875M

Verkoop

2M

7B

K/W

Sectorgemiddelde

35.807

90.831

EPS

3.88

Dividendrendement

4.01

Winstmarge

12.572

Werknemers

16,744

EBITDA

2B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+11.86% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.01%

2.20%

Volgende Winsten

6 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

7.5B

130B

Vorige openingsprijs

570.7

Vorige sluitingsprijs

569.8

Coloplast A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jan 2026, 19:05 UTC

Belangrijke Marktbewegers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 jan 2026, 23:41 UTC

Marktinformatie

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 jan 2026, 23:41 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 jan 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 jan 2026, 23:13 UTC

Acquisities, Fusies, Overnames

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 jan 2026, 23:10 UTC

Acquisities, Fusies, Overnames

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 jan 2026, 23:03 UTC

Marktinformatie

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 jan 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 jan 2026, 21:08 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 jan 2026, 20:39 UTC

Marktinformatie

Silver Settles at Another New High -- Market Talk

13 jan 2026, 20:21 UTC

Marktinformatie

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 jan 2026, 20:17 UTC

Marktinformatie

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 jan 2026, 19:08 UTC

Acquisities, Fusies, Overnames

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 jan 2026, 19:03 UTC

Winsten

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 jan 2026, 18:50 UTC

Winsten

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 jan 2026, 17:54 UTC

Marktinformatie

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 jan 2026, 17:49 UTC

Marktinformatie

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 jan 2026, 17:38 UTC

Marktinformatie

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

13 jan 2026, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

13 jan 2026, 17:19 UTC

Marktinformatie

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 jan 2026, 17:15 UTC

Marktinformatie

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Coloplast A-S (Class B) Prognose

Koersdoel

By TipRanks

11.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 901.38 DKK  11.86%

Hoogste 1,056 DKK

Laagste 720 DKK

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Coloplast A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

2

Buy

4

Hold

2

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat